The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis.
暂无分享,去创建一个
R. Thompson | S. Boorjian | B. Leibovich | C. Weight | Simon P. Kim | J. S. St. Sauver | M. McGree | D. Jacobson | R. Jeffrey Karnes | Bradley C. Leibovich | R. Houston Thompson | Debra J. Jacobson | Michaela E. McGree | Stephen A. Boorjian | Christopher J. Weight | Simon P. Kim | Jennifer St. Sauver | R. Karnes | R. Thompson
[1] C. Lee,et al. Role of androgen in prostate growth and regression: Stromal‐epithelial interaction , 1996, The Prostate. Supplement.
[2] D. Marchant,et al. Risk factors. , 1994, Obstetrics and gynecology clinics of North America.
[3] M. Barry,et al. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia. , 1998, The American journal of medicine.
[4] I. Thompson,et al. Epidemiology, Etiology, and Prevention of Prostate Cancer , 2012 .
[5] D. Bostwick,et al. The association of benign prostatic hyperplasia and cancer of the prostate , 1992, Cancer.
[6] C. Roehrborn,et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .
[7] R. Roberts,et al. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. , 2005, Mayo Clinic proceedings.
[8] S. Freedland,et al. Associations of benign prostatic hyperplasia with prostate cancer: the debate continues. , 2011, European urology.
[9] J. Oesterling,et al. Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? , 1995, Urology.
[10] C G Chute,et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.
[11] A. Wein,et al. Campbell-Walsh Urology , 2011 .
[12] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[13] D. Bostwick,et al. Human prostate cancer risk factors , 2004, Cancer.
[14] Culley Carson,et al. The role of dihydrotestosterone in benign prostatic hyperplasia. , 2003, Urology.
[15] B. Högstedt,et al. Calculated Fast-growing Benign Prostatic Hyperplasia , 2002, Scandinavian journal of urology and nephrology.
[16] F. Schröder,et al. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. , 2009, European urology.
[17] T. Wilt,et al. Correlates and prevalence of prostatitis in a large community-based cohort of older men. , 2005, Urology.
[18] Stig E Bojesen,et al. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. , 2011, European urology.
[19] W. Sakr,et al. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. , 2010, The Journal of urology.
[20] T. Guthrie,et al. Prostate cancer. , 2020, American family physician.
[21] Michael M Lieber,et al. The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.
[22] A. Lilienfeld,et al. Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. , 1974, Lancet.
[23] I. Thompson,et al. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. , 2011, American journal of epidemiology.
[24] D. Tindall,et al. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. , 2008, The Journal of urology.
[25] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.